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Abstract
In this study 45 isolates of Acinetobacter baumannii identiﬁed
from patients in intensive care units of three different hospitals
and from pressure ulcers in home care patients in Palermo, Italy,
during a 3-month period in 2010, were characterized. All iso-
lates were resistant to at least three classes of antibiotics, but
susceptible to colistin and tygecycline. Forty isolates were
non-susceptible to carbapenems. Eighteen and two isolates,
respectively, carried the blaOXA-23-like and the blaOXA-58-like
genes. One strain carried the VIM-4 gene. Six major rep-PCR
subtype clusters were deﬁned, including isolates from different
hospitals or home care patients. The sequence type/pulsed ﬁeld
gel electrophoresis group ST2/A included 33 isolates, and ST78/
B the remaining 12. ST2 clone proved to be predominant, but a
frequent involvement of the ST78 clone was evident.
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Multidrug-resistant Acinetobacter baumannii isolates are
emerging worldwide, necessitating larger use of broad-spec-
trum antibiotics, such as carbapenems. Since the early 1990s
the incidence of carbapenem resistance has also dramatically
risen on a global scale [1]. The ‘import and export’ of A. bau-
mannii between hospitals and long-term care facilities play an
important role in the epidemiology of multidrug-resistant
Acinetobacter baumannii [2]. Much less is known about the
home care (HC) setting, where control policies are especially
challenging, because patient management, including the per-
formance of proper hygienic practices, is unlikely to be con-
sistently applied [3,4].
Our study aimed to characterize A. baumannii isolates
from intensive care unit (ICU) patients and HC patients iden-
tiﬁed during a 3-month period in Palermo, Italy.
Acinetobacter baumannii isolates were collected from
patients admitted to three ICUs of three general acute hos-
pitals and from pressure ulcers of HC patients during the
period 1 October to 31 December 2010 in Palermo, Italy.
More details about the isolates are given in Table 1. Hospi-
tals A and C are non-university hospitals, whereas Hospital
B is the university teaching hospital. HC patients had been
admitted to the integrated HC delivery service (ADI) of the
Health District 10, Local Health Agency of Palermo (ASP
Palermo), Italy. The three hospitals and the HC service are
located in the inner city area.
All patients positive for A. baumannii were included in the
study and the A. baumannii strains were isolated and identi-
ﬁed by standard methods. In multiplex PCR only one isolate
per patient was used, when multiple isolates were available
that were indistinguishable based upon their antibacterial
resistance and rep-PCR pattern.
Antimicrobial susceptibility testing was undertaken using
the two commercial microdilution methods Phoenix 100 or
Vitek 2. The MICs of imipenem and meropenem were deter-
mined by using the Etest (AB Biodisk, Solna, Sweden).
Results were interpreted according to Clinical and Labora-
tory Standards Institute (CLSI) criteria for Acinetobacter spp.
[5].
Multiplex PCR was performed with primers that anneal to
blaOXA-51-like, blaOXA-23-like, blaOXA-24-like and blaOXA-58-like car-
bapenemases and the metallo-beta-lactamases blaIMP and
blaVIM, as previously described [6]. The newly described gene
blaOXA-143 was also searched for [7]. The rep-PCR DiversiLab
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Microbial Typing System (bioMe´rieux, Marcy l’E´toile,
France) was used to investigate the relationship among the
strains. Results were analysed with the DIVERSILAB software
using the modiﬁed Kullback–Leibler statistical method to
determine distance matrices and the unweighted pair group
method with arithmetic averages to create dendrograms. Iso-
lates that clustered 95% were considered related [8]. Pulsed-
ﬁeld gel electrophoresis (PFGE), after DNA digestion with
ApaI, was additionally used on 11 A. baumannii isolates,
selected upon the basis of the different rep-PCR clusters and
place of isolation. Multi-locus sequence typing was per-
formed, by using the primers and conditions described at
http://www.pasteur.fr/mlst, on 13 strains selected on the
basis of clustering by rep-PCR, carbapenemase gene pattern
and place of isolation. The sequences were analysed using the
online BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) software.
The isolates were then assigned to sequence types (STs)
using the tools on the A. baumannii multi-locus sequence typ-
ing webpage (http://pubmlst.org/abaumannii/). In addition, two
multiplex PCR were performed for identiﬁcation of the
ompA, csuE and blaOXA-51-like sequence groups (SGs) accord-
ing to Turton et al. [9].
Sixty-nine A. baumannii isolates were isolated from 37 dif-
ferent patients admitted to the three general ICUs in the
period under study. All subsequent analyses were conducted
on 37 non-repetitive isolates from different patients, of
whom 16 were from the Hospital A, ten from Hospital B
and 11 from Hospital C. Eight further isolates were collected
from pressure ulcers of HC patients in the same period.
All 45 isolates were resistant to at least three classes of
antibiotics. The rates of resistance to the majority of anti-
biotics tested varied between 80.0% and 100%, with the
exception of colistin and tygecycline. MICs for colistin and
tygecycline ranged between £ 0.5 lg/mL and 1 lg/mL and
£ 0.5 lg/mL and 4 lg/mL, respectively. All of the strains,
except for one from an HC patient that proved to be
TABLE 1. Characteristics of the Acinetobacter baumannii strains under study
Isolate Setting
MIC
meropenem
MIC
imipenem Carbapenemase
Sequence
group
Sequence
type
rep-PCR
subtype
cluster
1 Hospital A 8 4 OXA-58 1 2 A
2 Hospital A 32 32 OXA-23 1 2 A
3 Hospital A >32 >32 OXA-23 1 2 A
4 Hospital A >32 >32 OXA-23 1 2 A
5 Hospital A >32 >32 OXA-23 1 2 A
6 Hospital A >32 >32 OXA-23 1 2 A
7 Hospital A >32 >32 OXA-23 1 2 A
8 Hospital A 32 32 OXA-58 1 2 A
9 Hospital A >32 >32 OXA-23 1 2 A
10 Hospital B 16 16 OXA-23 1 2 A
11 Hospital B >32 >32 OXA-23 1 2 A
12 Hospital A >32 >32 OXA-23 1 2 A
13 Hospital B 4 4 Negative 1 2 B
14 Hospital B 8 8 OXA-23 1 2 B
15 Hospital C 8 4 OXA-23 1 2 B
16 Hospital A 4 8 OXA-23 1 2 B
17 Home care 8 8 Negative 4 2 B
18 Hospital C 16 32 Negative 1 2 B
19 Hospital A 32 8 Negative 1 2 B
20 Hospital B 8 4 Negative 1 2 B
21 Hospital B 16 8 VIM-4 1 2 B
22 Hospital B 8 8 Negative 1 2 B
23 Hospital A 8 8 Negative 1 2 B
24 Hospital B 8 8 Negative 1 2 B
25 Hospital B 8 8 Negative 1 2 B
26 Hospital B 16 8 Negative 1 2 B
27 Hospital A >32 >32 Negative 1 2 B
28 Home care 8 16 Negative 1 2 B
29 Hospital A >32 >32 OXA-23 1 2 C
30 Hospital A >32 >32 OXA-23 1 2 C
31 Hospital C 8 8 Negative new 78 D
32 Hospital C 16 32 Negative new 78 D
33 Hospital C >32 >32 Negative new 78 D
34 Hospital C 8 32 Negative new 78 D
35 Hospital C 8 8 Negative new 78 D
36 Home care >32 >32 Negative new 78 E
37 Home care 0.5 1 Negative new 78 E
38 Home care 8 16 Negative new 78 E
39 Home care 4 16 Negative new 78 E
40 Home care 1 0.25 Negative new 78 E
41 Home care 2 1 Negative new 78 E
42 Hospital C 4 16 Negative new 78 E
43 Hospital C >32 >32 OXA-23 1 2 F
44 Hospital C >32 >32 OXA-23 1 2 F
45 Hospital C >32 >32 OXA-23 1 2 F
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susceptible to third-generation cephalosporins and cefepime,
were resistant to ﬂuoroquinolones, piperacillin, piperacillin/
tazobactam, third-generation cephalosporins, cefepime and
aztreonam. As many as 34 of the 37 ICU isolates (91.9%)
were non-susceptible to meropenem (MIC ‡ 8 lg/mL) and
22 isolates (59.5%) were also non-susceptible to imipenem
(MIC ‡ 16 lg/mL). Acinetobacter baumannii isolates from HC
patients were more frequently susceptible to carbapenems
(Table 1).
All carbapenem-resistant strains were analysed for their
genetic determinants. Twenty of them were positive for
carbapenem-hydrolysing class D b-lactamase (CHDL) genes:
in particular, 18 carried the blaOXA-23-like and 2 the blaOXA-58-
like gene. One strain carried the metallo-b-lactamase VIM-4
gene. All isolates tested were also negative for the blaOXA-
143 sequence. Carbapenemases were not detected in 20 iso-
lates that were non-susceptible to imipenem or meropenem
or both. Presence of ISAba1 in the promoter region of the
blaOXA51 gene was not investigated because of the inconsis-
tent literature ﬁndings about its correlation with carbapenem
resistance and the possible involvement of alternative mecha-
nisms [10,11].
Six major DiversiLab rep-PCR subtype clusters (A–F)
were deﬁned, comprising two or more isolates (Fig. 1 and
Table 1). A close relationship was observed between the
presence of the blaOXA-23-like or blaOXA-58-like genes and attri-
bution with subtype cluster A (Table 1).
Two different STs were found: ST2, including 33 isolates,
and ST78, including the remaining 12. The ST2 isolates were
distributed within the three hospitals under study and the
HC patients. In contrast, the ST78 clone was detected in
Hospital C only and in six HC patients (Table 1). Sequence
grouping was assigned to all ST2 isolates, but one, the SG1.
The remaining isolate was attributed with SG4 (Table 1)
[12]. All the ST78 isolates shared a new SG [13]. Finally,
trilocus sequence-based typing attributed these 12 isolates
with the 3LST group 6 [13].
PFGE identiﬁed two major PFGE groups—A and B—
differing in at least seven bands. The isolates belonging to the
rep-PCR clusters A, B, C and F showed indistinguishable or
closely related PFGE proﬁles type A. The isolates belonging to
clusters D and E were assigned to three subtypes B—B1 to
B3–differing from each other by four to six bands (Table 1).
Overall, among the 45 isolates under study we found
seven rep-PCR patterns and two STs/PFGE groups, ST2/A
and ST78/B. Rep-PCR clustered together strains isolated
from different hospitals and home care, suggesting the spread
of some strains between different hospitals and HC patients.
Most isolates belonged to ST2, the so-called European
clone II, which has been repeatedly reported in Italy, with
previous studies showing that this clone is often responsible
for hospital outbreaks in southern Europe [8,14]. The so-
called ‘Italian clone’ ST78 was closely associated with one of
the three hospital ICUs and the HC setting. ST78, after being
ﬁrstly identiﬁed as a novel genotype in Naples, Italy, has been
FIG. 1. Dendrogram describing percentage similarities and banding
patterns of Acinetobacter baumannii by repetitive PCR, interpreted by
the Kullback–Leibler method. Molecular subtype clusters are also
identiﬁed.
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detected in northern and southern Italy, suggesting a wider
geographic dissemination than previously reported [15]. A
more recent study on 17 Italian hospitals has further con-
ﬁrmed the widespread occurrence of ST78 in Italy [16]. In
our study it unexpectedly appeared as a frequent colonizing
organism of pressure wounds in HC patients. This ﬁnding
warrants further investigation to conﬁrm the existence of a
community reservoir of this clone among HC patients or the
home environment or both.
Our study proved that the blaOXA-23-like gene was preva-
lent among the carbapenem-resistant isolates, unlike other
reports attributing a more prominent role in Italy to OXA-58
[16]. Acinetobacter baumannii isolates carrying the blaOXA-23
gene have been previously isolated elsewhere, exhibiting con-
sistently high levels of antimicrobial resistance [17]. More-
over, in one strain blaVIM-4 was detected, as previously
described in Greece [18].
In conclusion, molecular epidemiology of multidrug-resis-
tant A. baumannii in Palermo has underlined the predomi-
nance of the ST2 clone and the successful spread of the
ST78 clone among different ICUs and the HC setting. Addi-
tionally, molecular subtype clusters were identiﬁed within
each ST suggesting the dissemination of some strains through
the healthcare network, including acute general hospitals and
home care.
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